This excerpt taken from the EYE 8-K filed Apr 27, 2006.
Cataract/implant sales during the first quarter were $120.4 million, up 3.2 percent, net of a 5.1 percent decrease related to foreign currency. The growth reflected increased sales of technologically advanced products, partially offset by declining sales of discontinued, non-strategic products. Below are highlights of cataract/implant categories for the first quarter of 2006. Growth rates reflect comparisons to the same period in 2005 and include the impacts of foreign currency.
Intraocular lens (IOL) sales rose 8.9 percent to $66.3 million, due primarily to increased sales of Tecnis® and other premium IOLs, which were partially offset by the accelerated phase-out of older-generation silicone and PMMA (polymethyl methacrylate) IOLs. AMOs refractive IOLs Tecnis® Multifocal, ReZoomTM and VerisyseTM contributed $10.3 million to IOL sales in the quarter. This compared to nearly $9 million in the fourth quarter of 2005 and about $4 million in the year-ago quarter. The company now expects to generate between $50 million and $60 million in 2006 refractive implant sales, representing a $5 million increase over its prior forecast.
Phacoemulsification sales rose 13.8 percent to $21.4 million. Strong sales of AMOs proprietary Sovereignâ systems with WhiteStarâ technology, as well as the surgical packs and accessories that support these systems, led this growth.
Viscoelastics sales declined 10.2 percent to $28.9 million, as Healon® product performance was masked by declining sales of discontinued viscoelastics, reimbursement pressures in certain international markets and unfavorable foreign currency translations.
This excerpt taken from the EYE 8-K filed Nov 2, 2005.